NCT05697211已完成4 期
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Change in haemoglobin level from baseline to week 16
研究概览
简要总结
This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men, women*, inter/diverse aged ≥ 18 at day of inclusion
- •Signed written informed consent from patient prior to any study-related procedure and willingness to comply with treatment and follow-up procedures
- •Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial
- •Patients with chronic heart failure with an Left ventricular ejection fraction (LVEF)<50% (Heart failure with reduced ejection fraction (HFrEF), Heart failure with a mid-range ejection fraction (HFmrEF)) or patients with chronic heart failure with an EF≥50% (HFpEF) and New York Heart Association functional class II-IV
- •6 min walk distance >50 m
- •Mild-to-moderate anaemia and iron -deficiency as defined by a haemoglobin concentration ≥8 g/dl and <12 g/dl in females or ≥9 g/dl and <13 g/dl in males, and serum ferritin <100 µg/l, or 100-299 µg/l and transferrin saturation <20% at screening
- •*Women without childbearing potential defined as follows:
- •females before menarche (if applicable)
- •at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
- •hysterectomy or uterine agenesis or
- •≥ 50 years and in postmenopausal state > 1 year or
- •< 50 years and in postmenopausal state > 1 year with serum Follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or
- •*Women of childbearing potential:
- •who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or
- •who have sexual relationships with female partners only and/or with sterile male partners or
- •who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception** from the time of screening until end of the clinical trial.
- •The following methods of contraception are acceptable): e.g.
- •progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- •male or female condom with or without spermicide
- •cap, diaphragm or sponge with spermicide
排除标准
- •Active haematological disorders other than anaemia and/or iron -deficiency
- •Other medical condition that according to the investigator's assessment is causing or contributing to anaemia
- •Active malignancy or currently receiving chemotherapy or radiotherapy
- •Active infectious disease
- •Active bleeding
- •Severe renal insufficiency (glomerular filtration rate (GFR) < 20ml/min or requiring dialysis)
- •Severe liver injury as indicated by serum aminotransferases >3 x upper limit of normal or bilirubin levels >50 µmol/l
- •Ongoing oral or intravenous iron supplementation
- •Concomitant erythropoietin medication
- •Erythropoiesis stimulating agents (ESA), i.v. iron or blood transfusion administered in last 3 months and oral iron (>100 mg/day) in previous 4 weeks
- •Pregnancy or lactation period
- •Subject has received any investigational medication or any investigational devices within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/ devices trial, or is scheduled to receive investigational drug/devices during the course of the study
- •Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product
- •Known haemochromatosis or other iron overload syndromes
- •Patients with severe, uncorrected valvular heart disease
- •Clinical evidence of Acute coronary syndrome (ACS), Transient ischaemic attack (TIA) or stroke within the last 30 days
- •Coronary artery bypass graft (CABG), Percutaneous transluminal coronary angioplasty (PTCA), cardiac device implant/resynchronisation therapy or major surgery leading to significant blood loss within last 30 days
- •Planned CABG, PTCA, cardiac device implant/resynchronisation therapy or major surgery
- •Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects with Vitamin B12 or folic acid deficiency who in the opinion of the Investigator are stable and asymptomatic will be permitted.
研究组 & 干预措施
Feraccru® 30 mg hard capsules
Experimental
Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily p.o., morning and evening, on an empty stomach
干预措施: Ferric maltol 30 mg (Feraccru®) (Drug)
结局指标
主要结局
Change in haemoglobin level from baseline to week 16
时间窗: baseline to week 16
次要结局
- Change in echocardiographic marker of left ventricular function from baseline to week 16(baseline to week 16)
- Change in echocardiographic markers of right ventricular function from baseline to week 16(baseline to week 16)
- Liver: Change in Alanine transaminase (ALT) from baseline to week 16(baseline to week 16)
- Liver: Change in Aspartate transaminase (AST) from baseline to week 16(baseline to week 16)
- Liver: Change in Bilirubin from baseline to week 16(baseline to week 16)
- Kidney: Change in Creatinine (+Glomerular filtration rate) from baseline to week 16(baseline to week 16)
- Change in transferrin saturation from baseline to week 16(baseline to week 16)
- Change in serum ferritin from baseline to week 16(baseline to week 16)
- Change in 6 min walking distance from baseline to week 16(baseline to week 16)
- Change in Health-related quality of life (HRQoL, measured by KCCQ-12) from baseline to week 16(baseline to week 16)
- Change in echocardiographic markers of left ventricular function from baseline to week 16(baseline to week 16)
- Change in soluble transferrin receptor 1 from baseline to week 16(baseline to week 16)
- Change in serum N-terminal pro brain natriuretic peptide (NT-proBNP) from baseline to week 16(baseline to week 16)
- Liver: Change in Albumin from baseline to week 16(baseline to week 16)
- Change in New York Heart Association (NYHA) class from baseline to week 16(baseline to week 16)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHDGraft vs Host DiseaseNCT06568328Fujian Medical University17
招募中
1 期
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid TumorsAdvanced Solid TumorsNCT05976906Zhejiang University36
终止
1 期
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaGlioblastomaNCT03422094Washington University School of Medicine3
Unknown
1 期
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsMesothelin-positive Advanced Malignant Solid TumorsNCT05848999Zhejiang University87
尚未招募
1 期
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsSolid TumorNCT05775666Peking University87